Lineage Cell Therapeutics, Inc. (LCTX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 2,765 | 1,502 | 3,779 | |
| Cost of sales | - | 36 | 38 | |
| Cost of royalties | 39 | - | - | |
| Research and development | 3,106 | 3,114 | 3,171 | |
| Loss on impairment of intangible asset (note 6 and note 13) | 14,840 | - | - | |
| General and administrative | 4,560 | 4,857 | 4,410 | |
| Total operating expenses | 22,545 | 8,007 | 7,619 | |
| Loss from operations | -19,780 | -6,505 | -3,840 | |
| Other income (expense), net | 26 | -185 | - | |
| Interest income, net | 454 | 478 | 397 | |
| Foreign currency transaction gain (loss), net | 1,678 | -231 | 448 | |
| Change in fair value of warrant liability | 12,740 | -2,305 | - | |
| Loss on marketable equity securities, net | -2 | -5 | -6 | |
| Total other income (expenses) | -10,584 | 2,362 | 839 | |
| Loss before income taxes | - | - | -3,001 | |
| Net loss | -30,364 | -4,143 | -3,001 | |
| Net (income) loss attributable to noncontrolling interest | 100 | -4 | 33 | |
| Net loss attributable to lineage | -30,464 | -4,139 | -3,034 | |
| Basic net loss per share | -0.13 | -0.02 | -0.02 | |
| Diluted net loss per share | -0.13 | -0.02 | -0.02 | |
| Weighted average number of shares outstanding, basic, total | 228,356,000 | 226,054,000 | 188,835,000 | |
| Weighted average number of shares outstanding, diluted | 228,356,000 | 226,054,000 | 188,835,000 | |